Compounded Semaglutide Regulations 2026: What Patients Need to Know

*This article is for informational purposes only. It is not medical advice. Speak with a licensed healthcare provider before starting, stopping, or changing any medication.*

---

If you have been using compounded semaglutide or thinking about starting it, the regulatory landscape around this medication has changed significantly over the past year. Federal rules that once allowed widespread compounding have tightened. Courts have weighed in. The FDA issued new policy clarifications as recently as April 2026.

This guide explains what happened, where things stand today, and what it means for you as a patient trying to make an informed decision.

---

Why Compounded Semaglutide Existed in the First Place

To understand the current situation, it helps to know why compounded semaglutide became so widely available in the first place.

Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management) are both brand-name products manufactured by Novo Nordisk. Both use semaglutide as their active ingredient. When demand for these medications surged beginning around 2022, supply could not keep up. The FDA formally added semaglutide to its Drug Shortage List, which triggered a specific legal exemption.

Under federal law (specifically, Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act), licensed compounding pharmacies may legally prepare medications that are essentially copies of commercially available drugs when those drugs are on the FDA shortage list. This is not a loophole. It is a patient-access provision written into law to ensure that people can still get medications when brand-name supply fails.

With semaglutide on the shortage list, licensed compounding pharmacies could legally prepare and dispense it. Telehealth platforms, including Prescriva, partnered with state-licensed 503A pharmacies to connect patients with clinician-prescribed compounded semaglutide at a fraction of the brand-name cost. Millions of patients accessed treatment this way.

---

February 2025: The FDA Removes Semaglutide from the Shortage List

On February 21, 2025, the FDA announced that semaglutide injection products were no longer in shortage. The agency determined that supply of Ozempic and Wegovy had stabilized sufficiently to resolve the shortage designation.

This was a significant legal trigger. Once a drug leaves the shortage list, the shortage-based compounding exemption no longer applies. Compounders who had been operating legally under that exemption could no longer rely on it.

The FDA set enforcement deadlines reflecting this change:

• 503A pharmacies (state-licensed, patient-specific compounders): Enforcement discretion ended April 22, 2025.
• 503B outsourcing facilities (larger compounders that supply healthcare facilities): Enforcement discretion ended May 22, 2025.

In plain terms: after those dates, compounding semaglutide simply because it had been on the shortage list was no longer a defensible legal position.

---

The Legal Challenge: Outsourcing Facilities Association v. FDA

The compounding industry did not accept the FDA's decision without a fight. The Outsourcing Facilities Association (OFA), a trade group representing FDA-registered 503B compounders, filed suit challenging the shortage removal as arbitrary and unlawful.

The court was not persuaded. On April 24, 2025, a federal district court denied the plaintiffs' request for a preliminary injunction, allowing the FDA's enforcement timeline to proceed.

That ruling mattered for patients because it removed any near-term legal protection that had kept larger 503B outsourcing facilities in the market for compounded semaglutide. Many of the highest-volume compounded semaglutide suppliers operated as 503B facilities. After the ruling, their ability to continue compounding semaglutide legally became much more limited.

---

What Is Still Legal: The Current Framework

This is where the picture gets more nuanced, and where many patients get confused by incomplete or outdated information they find online.

Compounded semaglutide is not categorically banned. Legitimate, patient-specific compounding by state-licensed 503A pharmacies can still occur. But the conditions are narrower than they were when the shortage exemption was active.

The April 2026 FDA Clarification

On April 1, 2026, the FDA issued updated guidance clarifying exactly when compounded semaglutide qualifies for protection under Section 503A. The agency defined what it means for a compounded product to be "essentially a copy" of a commercially available drug.

According to that guidance, a compounded semaglutide product is considered essentially a copy of Ozempic or Wegovy if it:

1. Contains the same active pharmaceutical ingredient (semaglutide) at the same, similar, or easily substitutable strength, and
2. Is administered by the same route (for example, subcutaneous injection, as with both commercial products).

Importantly, the FDA also addressed combination products. A compounded semaglutide product that adds another ingredient, such as vitamin B12, is still considered essentially a copy if the strengths of both ingredients are within 10% of commercially available products administered the same way. This means that vitamin B12 additions do not automatically create a meaningfully different compound that escapes the "essentially a copy" standard.

The 503A Safe Harbor

The April 2026 guidance also preserved a meaningful protection for smaller, patient-specific 503A compounders.

The FDA stated that it does not currently intend to take enforcement action against a 503A compounding pharmacy for compounding essentially a copy of a commercially available product, if the pharmacy fills four or fewer prescriptions per calendar month for that specific formulation.

This is a small-volume threshold designed to protect genuine patient-specific compounding while limiting large-scale commercial production disguised as individual prescriptions.

For a pharmacy to qualify, every prescription must also be:

• Received from an individual prescriber for a specific, identified patient.
• Different in some clinically meaningful way from what is commercially available, or justified by a documented patient-specific need.

*Patient-specific 503A compounding pharmacies can still legally prepare semaglutide for qualifying patients under current FDA policy.*

---

Who Still Qualifies for Compounded Semaglutide

Given the current framework, compounded semaglutide remains legally accessible through 503A pharmacies for patients who meet documented clinical criteria. Three pathways are recognized under current regulatory and clinical practice:

1. Allergy to an Inactive Ingredient

Ozempic and Wegovy both contain polysorbate 80 as an inactive ingredient. Patients with documented allergies or hypersensitivity reactions to polysorbate 80 cannot safely use the commercial products. A compounded formulation using a different excipient may be clinically appropriate and represents a genuine patient-specific need.

2. Need for a Dosage Strength Not Commercially Available

Ozempic is available in fixed doses (0.5 mg, 1 mg, and 2 mg). Wegovy follows a fixed titration schedule (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg). Some patients, particularly those who experience significant side effects at standard starting doses, may benefit from a slower dose escalation using smaller increments not commercially available. A prescriber who documents this clinical rationale is providing the basis for a patient-specific compounded formulation.

3. Clinical Need for a Different Route of Administration

Standard semaglutide is a subcutaneous injection. Some patients have documented contraindications to self-injection (for example, severe needle phobia with a clinically documented impact on adherence, or specific physical limitations). A compounded sublingual or oral preparation may be appropriate in these cases, though it is important to understand that oral semaglutide formulations differ significantly in bioavailability from injectable versions.

In all three cases, the prescribing provider should document the specific clinical rationale in the patient's medical record. This documentation is not bureaucratic box-checking. It is the foundation that makes the prescription legally defensible under current FDA policy.

---

What Changed for 503B Outsourcing Facilities

The situation for 503B facilities is more restrictive. These larger operations are regulated differently from 503A pharmacies because they can supply medications without patient-specific prescriptions, filling bulk orders for healthcare facilities.

Since semaglutide was removed from the FDA shortage list and semaglutide does not currently appear on the FDA's 503B bulk drug substances list, 503B outsourcing facilities cannot legally compound semaglutide under current policy. The pathway that allowed bulk compounding during the shortage period is closed.

This effectively removed the largest-volume compounded semaglutide producers from the market. Many of the direct-to-consumer telehealth companies that were shipping very high volumes of compounded semaglutide were sourcing from 503B facilities. Those supply chains are no longer legally viable without a new shortage designation or a change to the 503B bulk substances list.

---

*FDA enforcement actions beginning in late 2025 targeted unlicensed compounders, misleading marketing, and poor-quality ingredient sourcing.*

---

The FDA's Enforcement Priorities

The regulatory picture shifted not just in terms of which pharmacies can compound, but in terms of what the FDA is actively targeting. Beginning in late 2025 and continuing into 2026, the FDA issued more than 55 warning letters to online sellers of compounded GLP-1 medications and identified several enforcement priorities:

• Compounding without documented medical necessity. Mass-producing essentially identical products for any patient who asks, without individual clinical justification, does not qualify as patient-specific compounding.
• Unlicensed manufacturing. Any entity producing injectable medications without state pharmacy licensure and appropriate federal oversight is operating illegally.
• Misleading marketing. Claiming that a compounded product is "the same as Ozempic" or implying FDA approval where none exists violates FTC advertising rules and FDA labeling law.
• Poor API sourcing. Using research-grade semaglutide peptides, which are not manufactured for human use, creates real safety risks. Reputable compounding pharmacies source active pharmaceutical ingredients from FDA-registered manufacturers.
• Improper storage and shipping. Injectable medications require cold-chain shipping and proper storage to maintain stability and sterility.

These enforcement priorities are worth keeping in mind when evaluating any provider. They represent the practices the FDA considers most dangerous to patients.

---

How to Evaluate a Provider in the Current Environment

If you are considering compounded semaglutide or are currently using it, the questions below will help you assess whether your provider operates within the current legal framework.

Does the provider use a 503A-licensed compounding pharmacy? A licensed 503A pharmacy is state-licensed and operates under state pharmacy board oversight. Ask which pharmacy prepares your medication and verify its license.

Does your prescriber document a clinical rationale? Your provider should document why compounded semaglutide is appropriate for you specifically, not just issue a prescription on demand. This documentation protects you and makes the prescription legally defensible.

Is the API sourced from an FDA-registered facility? Ask whether the pharmacy uses pharmaceutical-grade semaglutide from an FDA-registered active ingredient manufacturer. This is a basic quality standard, not an advanced one.

Is the product tested for potency and sterility? Reputable compounding pharmacies conduct or commission third-party testing to verify that each batch meets labeled specifications. Ask for certificates of analysis.

Is the provider making compliant claims? Any website that says compounded semaglutide is "FDA-approved" or "the same as Wegovy" is making false claims. This is a meaningful red flag about the provider's reliability and commitment to regulatory compliance.

---

What Prescriva Does

Prescriva is a telehealth platform and management services organization. We do not manufacture medications, dispense prescriptions, or make clinical decisions. All prescribing decisions are made by independently licensed healthcare providers in Prescriva's affiliated network, and all medications are dispensed by licensed, state-registered compounding pharmacies.

Licensed compounding pharmacies in Prescriva's affiliated network operate as 503A compounders. Prescriptions are issued for individual patients based on provider-documented clinical rationale. The regulatory landscape is taken seriously because patients deserve providers who do.

Compounded semaglutide is not FDA-approved. Licensed compounding pharmacies follow established quality standards, and independently licensed healthcare providers in Prescriva's affiliated network are equipped to assess whether compounded semaglutide is appropriate for your individual situation.

*Note: Consult your healthcare provider before starting any new medication. Results vary by individual. This is not medical advice.*

---

The Bottom Line

The regulatory environment around compounded semaglutide has tightened considerably since early 2025, and as of April 2026 it continues to evolve. Here is the clearest summary of where things stand:

• The FDA shortage exemption is gone. Semaglutide was removed from the shortage list in February 2025, and that legal basis for widespread compounding no longer applies.
• 503A patient-specific compounding is still legal, within limits. A state-licensed 503A pharmacy can prepare compounded semaglutide for an individual patient with a documented clinical need. Volume limits and patient-specific prescription requirements apply.
• 503B bulk compounding is not currently legal for semaglutide. Large outsourcing facilities cannot lawfully compound semaglutide without a new shortage designation or inclusion on the 503B bulk substances list.
• FDA enforcement is active. The agency issued warning letters to more than 55 sellers in late 2025 and has stated clear enforcement priorities targeting unlicensed production, misleading marketing, and poor-quality API sourcing.
• Patients have legitimate pathways. If you have a documented allergy to a commercial product's inactive ingredient, a need for a dose not commercially available, or a clinically justified need for a different route of administration, compounded semaglutide may still be an appropriate and legally available option for you, through a qualified provider and licensed pharmacy.

If you are uncertain about your situation, the right first step is a conversation with a licensed healthcare provider who understands both the clinical and the regulatory context. That is exactly what a good telehealth evaluation should offer you.

---

*Compounded medications are not FDA-approved. Always verify that your pharmacy is licensed in your state and that your prescription includes documented clinical rationale. Consult your healthcare provider with questions about your specific treatment plan.*

---

Sources used in this article:

• FDA Drug Shortage List: semaglutide removal, February 2025
• *Outsourcing Facilities Association v. FDA*, district court ruling, April 24, 2025
• FDA Policy Clarification on Compounded GLP-1 Products, April 1, 2026 (Foley & Lardner summary)
• FDA Drug Alerts and Statements: GLP-1 supply stabilization update
• Wilding JPH et al. (STEP 1 trial). *New England Journal of Medicine*, 2021 (PMID: 33567185): semaglutide 2.4 mg achieved 14.9% average body weight reduction vs. 2.4% placebo over 68 weeks.